Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial - PubMed
3 days ago
- #perfusion
- #ulcerative colitis
- #hyperbaric oxygen therapy
- Hyperbaric oxygen therapy (HBOT) is investigated as an adjunctive treatment for moderate-to-severe refractory ulcerative colitis in biologic-experienced patients.
- The PARADOX trial, a prospective pilot study, involved 16 patients receiving either 10 or 20 daily HBOT sessions, with outcomes assessed at week 12.
- Composite clinical and endoscopic response was achieved in 2 out of 8 patients in the 10-session group and 4 out of 8 in the 20-session group.
- Clinical responders showed improved bowel perfusion via contrast-enhanced ultrasound, while non-responders experienced a decline, indicating a perfusion-based mechanism.
- HBOT was well-tolerated with no serious adverse events, supporting further evaluation in randomized trials for refractory ulcerative colitis.